Solvonis Therapeutics (SVNS LN)

Analysis

Industrials • United Kingdom

Solvonis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines for high-burden central nervous system (CNS) disorders, with an initial focus on addiction and mental health. The company is advancing a pipeline of repurposed and novel compounds, including lead programs addressing Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD). Headquartered in London, United Kingdom, the company was founded in 2017.

Refresh

Exchange Announcement • 13 Oct 2026 13:00

MOU Reached with ICAD

Exchange Announcement • 06 Oct 2026 13:00

Investor Webinar – 15 October 2026

Exchange Announcement • 30 Sep 2026 18:06

Notification of Admission of Shares and TVR

Exchange Announcement • 30 Sep 2026 18:05

Unaudited interim results

Exchange Announcement • 29 Sep 2026 13:00

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MOU Reached with ICAD

Investor Webinar – 15 October 2026

Notification of Admission of Shares and TVR

Unaudited interim results

New Analysis Identifies Major AUD Breakthrough